Tools
Tools
Morton, Ben 
ORCID: https://orcid.org/0000-0002-6164-2854, Jambo, Kondwani ORCID: https://orcid.org/0000-0002-3195-2210, Chikaonda, Tarsizio, Rylance, Jamie ORCID: https://orcid.org/0000-0002-2323-3611, Henrion, Marc, Banda, Ndaziona Peter, Nsomba, Edna, Gondwe, Joel, Ferreira, Daniela ORCID: https://orcid.org/0000-0002-0594-0902 and Gordon, Stephen ORCID: https://orcid.org/0000-0001-6576-1116
(2021)
'The influence of pneumococcal conjugate vaccine-13 on nasal colonisation in a controlled human infection model of pneumococcal carriage in Malawi: a double-blinded randomised controlled trial protocol'. Wellcome Open Research, Vol 6, p. 240.
![[img]](https://archive.lstmed.ac.uk/style/images/fileicons/text.png) |
Text
Ben Morton - 300821.docx - Accepted Version Restricted to Repository staff only Download (249kB) |
|
|
Text
Ben Morton - Welcome Open Nov 2021.pdf - Published Version Available under License Creative Commons Attribution. Download (815kB) | Preview |
Abstract
Streptococcus pneumoniae is the leading cause of morbidity and mortality due to community acquired pneumonia, bacterial meningitis and bacteraemia worldwide. Pneumococcal conjugate vaccines protect against invasive disease, but are expensive to manufacture, limited in serotype coverage, associated with serotype replacement, and demonstrate reduced effectiveness against mucosal colonisation. For Malawi, nasopharyngeal carriage of vaccine-type pneumococci is common in vaccinated children despite national roll-out of 13-valent pneumococcal conjugate vaccine (PCV13) since 2011. Our team has safely transferred an established experimental human pneumococcal carriage method from Liverpool School of Tropical Medicine to the Malawi-Liverpool Wellcome Trust Clinical Research Programme, Malawi.
This study will determine potential immunological mechanisms for the differential effects of PCV13 on nasal carriage between healthy Malawian and UK populations. We will conduct a double-blinded randomised controlled trial to vaccinate (1:1) participants with either PCV13 or control (normal saline). After a period of one month, participants will be inoculated with S. pneumoniae serotype 6B to experimentally induce nasal carriage using the EHPC method. Subsequently, participants will be invited for a second inoculation after one year to determine longer-term vaccine-induced immunological effects. Primary endpoint: detection of inoculated pneumococci by classical culture from nasal wash recovered from the participants after pneumococcal challenge. Secondary endpoints: local and systemic innate, humoral and cellular responses to PCV-13 with and without pneumococcal nasal carriage
The primary objective of this controlled human infection model study is to determine if PCV-13 vaccination is protective against pneumococcal carriage in healthy adult Malawian volunteers. This study will help us to understand the observed differences in PCV-13 efficacy between populations and inform the design of future vaccines relevant to the Malawian population.
Statistics
Actions (login required)
 |
Edit Item |